Cancer associated thrombosis in pediatric patients

Assaf Arie Barg, Gili Kenet*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The etiology of pediatric cancer associated thrombosis (CAT) is multifactorial and may reflect pro-coagulant alterations of the hemostatic system induced by presence of cancer itself or by therapeutic chemotherapy, tumor mass effects, tumor thrombi, and inherited thrombophilia. Age, diagnosis of hematological malignancy and presence of a central venous line significantly increase the risk of thrombosis. With over 80% cure rates of childhood cancer, strategies for prevention as well as for early diagnosis and optimal treatment of (thromboembolism) TE in children with malignancies are of major importance. Currently use of therapeutic low molecular heparin (LMWH) still prevails, as prospective studies and real world data regarding Direct oral anticoagulant (DOAC) use for treatment or prevention of pediatric CAT are scarce. The following review will address the epidemiology, etiology and risk factors for CAT in children, and describe the presently available evidence associated with anticoagulant therapy and prevention strategies.

Original languageEnglish
Article number101352
JournalBest Practice and Research: Clinical Haematology
Volume35
Issue number1
DOIs
StatePublished - Mar 2022

Funding

FundersFunder number
Alnylam
BPL
Pfizer
Bayer
Roche
Takeda Pharmaceutical Company
Shire
CSL Limited

    Keywords

    • Cancer
    • Central venous line
    • DOAC
    • Leukemia
    • Pediatric
    • Thrombosis

    Fingerprint

    Dive into the research topics of 'Cancer associated thrombosis in pediatric patients'. Together they form a unique fingerprint.

    Cite this